KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBT (2016 - 2025)

Historic EBT for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $1.8 billion.

  • Thermo Fisher Scientific's EBT rose 482.2% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 billion, marking a year-over-year increase of 380.34%. This contributed to the annual value of $7.0 billion for FY2024, which is 1173.39% up from last year.
  • Per Thermo Fisher Scientific's latest filing, its EBT stood at $1.8 billion for Q3 2025, which was up 482.2% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Thermo Fisher Scientific's EBT peaked at $2.8 billion during Q2 2021, and registered a low of $1.4 billion during Q2 2023.
  • Moreover, its 5-year median value for EBT was $1.8 billion (2023), whereas its average is $1.9 billion.
  • As far as peak fluctuations go, Thermo Fisher Scientific's EBT surged by 23248.79% in 2021, and later plummeted by 4633.86% in 2023.
  • Over the past 5 years, Thermo Fisher Scientific's EBT (Quarter) stood at $1.9 billion in 2021, then decreased by 4.56% to $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then grew by 11.55% to $1.9 billion in 2024, then decreased by 5.92% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.6 billion during Q1 2025.